193 related articles for article (PubMed ID: 34533824)
21. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
[TBL] [Abstract][Full Text] [Related]
22. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
Tang AY; Zhou M; Maillis AN; Lai KW; Lane PA; Snyder AB
Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749
[TBL] [Abstract][Full Text] [Related]
23. Profile of Medicaid enrollees with sickle cell disease: A high need, high cost population.
Grady A; Fiori A; Patel D; Nysenbaum J
PLoS One; 2021; 16(10):e0257796. PubMed ID: 34705847
[TBL] [Abstract][Full Text] [Related]
24. Characterization of opioid use in sickle cell disease.
Han J; Zhou J; Saraf SL; Gordeuk VR; Calip GS
Pharmacoepidemiol Drug Saf; 2018 May; 27(5):479-486. PubMed ID: 28815799
[TBL] [Abstract][Full Text] [Related]
25. Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study.
As-Sanie S; Soliman AM; Evans K; Erpelding N; Lanier RK; Katz NP
J Minim Invasive Gynecol; 2021 Feb; 28(2):297-306.e2. PubMed ID: 32531340
[TBL] [Abstract][Full Text] [Related]
26. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.
Reddy PS; Cai SW; Barrera L; King K; Badawy SM
Ann Med; 2022 Dec; 54(1):683-693. PubMed ID: 35234095
[TBL] [Abstract][Full Text] [Related]
27. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936
[TBL] [Abstract][Full Text] [Related]
29. Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.
Madkhali MA; Abusageah F; Hakami F; Zogel B; Hakami KM; Alfaifi S; Alhazmi E; Zaalah S; Trabi S; Alhazmi AH; Mohrag M; Malhan H
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256385
[No Abstract] [Full Text] [Related]
30. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease.
Badawy SM; Thompson AA; Holl JL; Penedo FJ; Liem RI
Pediatr Hematol Oncol; 2018; 35(5-6):297-308. PubMed ID: 30636474
[TBL] [Abstract][Full Text] [Related]
31. Indication-Specific Opioid Prescribing for US Patients With Medicaid or Private Insurance, 2017.
Mikosz CA; Zhang K; Haegerich T; Xu L; Losby JL; Greenspan A; Baldwin G; Dowell D
JAMA Netw Open; 2020 May; 3(5):e204514. PubMed ID: 32391892
[TBL] [Abstract][Full Text] [Related]
32. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
33. Changes in opioid prescriptions for Medicaid-enrolled children and young adults, 2012-2016.
Masonbrink A; Richardson T; Delzeit J; Miller MK; Hall M; Catley D
J Opioid Manag; 2020; 16(6):451-460. PubMed ID: 33428192
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
35. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic: A Qualitative Study.
Sinha CB; Bakshi N; Ross D; Krishnamurti L
JAMA Netw Open; 2019 May; 2(5):e194410. PubMed ID: 31125105
[TBL] [Abstract][Full Text] [Related]
36. Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not.
Nwenyi E; Leafman J; Mathieson K; Ezeobah N
Int J Health Care Qual Assur; 2014; 27(6):468-81. PubMed ID: 25115050
[TBL] [Abstract][Full Text] [Related]
37. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
Newman TV; Yang J; Suh K; Jonassaint CR; Kane-Gill SL; Novelli EM
JAMA Netw Open; 2023 Nov; 6(11):e2344546. PubMed ID: 37991760
[TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea use among children with sickle cell anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State.
Anders DG; Tang F; Ledneva T; Caggana M; Green NS; Wang Y; Sturman LS
Am J Prev Med; 2016 Jul; 51(1 Suppl 1):S31-8. PubMed ID: 27320463
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
